Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (120)
  • HER
    (16)
  • Apoptosis
    (12)
  • Autophagy
    (10)
  • Src
    (8)
  • FGFR
    (6)
  • PDGFR
    (6)
  • VEGFR
    (6)
  • BTK
    (4)
  • Tyrosine Kinases
    (4)
Filter
Search Result
Results for "

ErbB-1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    125
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    4
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    10
    TargetMol | Natural_Products
  • Recombinant Protein
    43
    TargetMol | Recombinant_Protein
  • Antibody Products
    41
    TargetMol | Antibody_Products
Gefitinib
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Trastuzumab
T9912180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Osimertinib
Mereletinib, AZD-9291
T24901421373-65-0
Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Cetuximab
Cetuximab (anti-EGFR), C225
T9905205923-56-4
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
PF-06459988
T164921428774-45-1In house
PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor. PF-06459988 has high efficiency and high affinity for EGFRs double mutants containing T790M, and has minimal activity against WT EGFR. PF-06459988 makes a candidate drug for the treatment of cancer.
  • Inquiry Price
6-8weeks
Size
QTY
Lapatinib
GW572016, GSK572016
T0078231277-92-2
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2 10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
  • Inquiry Price
Size
QTY
Erlotinib
R1415, OSI-744, NSC 718781, CP358774
T0373183321-74-6
Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
  • Inquiry Price
Size
QTY
Genistein
NPI 031L
T1737446-72-0
Genistein (NPI 031L) is a naturally occurring soy isoflavone, a multi-targeted tyrosine kinase inhibitor. Genistein has antitumor, antioxidant, and anthelmintic properties, and also produces estrogen-like effects in the body.
  • Inquiry Price
Size
QTY
Avitinib
AC0010
T30241557267-42-1
Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of Ys, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.
  • Inquiry Price
Size
QTY
EGFR-IN-12
EGFR Inhibitor
T5168879127-07-8
EGFR-IN-12 (EGFR Inhibitor) is a cell permeable and selective inhibitor of EGFR kinase (IC50: 21 nM) and blocks receptor autophosphorylation in cells.
  • Inquiry Price
Size
QTY
Canertinib
PD-183805, CI-1033
T6136267243-28-7
Canertinib (CI-1033) is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
  • Inquiry Price
Size
QTY
wz4002
T62381213269-23-8
WZ4002 is a mutant-selective EGFR inhibitor for EGFR(L858R) and EGFR(T790M) with IC50 of 2 nM 8 nM.
  • Inquiry Price
Size
QTY
Butein
2',3,4,4'-tetrahydroxy Chalcone
T6427487-52-5
Butein is a cAMP-specific PDE inhibitor, protein tyrosine kinase inhibitor, and SIRT1 activator. It sensitizes HeLa cells to Cisplatin by targeting FoxO3a via the AKT and ERK p38 MAPK pathways.
  • Inquiry Price
Size
QTY
egfr/erbb-2/erbb-4 inhibitor-2
EGFR ErbB2 Inhibitor
T21954179248-61-4
EGFR ErbB-2 ErbB-4 inhibitor-2 (EGFR ErbB2 Inhibitor) is a cell-permeable compound that inhibits EGFR and c-ErbB2 with IC50 values of 20 nM and 79 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AV-412
MP412
T10419451493-31-5
AV-412 (MP412) is an EGFR inhibitor for EGFR, EGFR T790M, EGFR L858R, EGFR L858R T790M, and ErbB2, with IC50 values of 0.75, 0.79, 0.5, 2.3, and 19 nM, respectively.
  • Inquiry Price
Size
QTY
BMS-690514
T14677859853-30-8
BMS-690514 is a potent, orally active inhibitor of EGFR and VEGFR, with IC50 values of 5 nM for EGFR, 20 nM for HER 2, and 60 nM for HER 4.
  • Inquiry Price
7-10 days
Size
QTY
WHI-P180
Janex 3
T2032211555-08-7
WHI-P180 (Janex 3) is a potent inhibitor of EGFR and Cdk2, with IC50 values of 4.0 µM and 1.0 µM, respectively.
  • Inquiry Price
Size
QTY
Tyrphostin 23
Tyrphostin A23, TX 825, RG-50810, AG18
T2063118409-57-7
Tyrphostin 23 (AG18) inhibits EGFR with IC50 of 35 μM.
  • Inquiry Price
Size
QTY
pf-6274484
PF 6274484
T223961035638-91-5
PF-6274484, a high affinity, irreversible covalent inhibitor of EGFR kinase with Ki of 0.14 nM, inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R T790M in H1975 cells with IC50 of 5.8 nM and 6.6 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
pd-161570
PD 161570
T23127192705-80-9
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. It also inhibits the PDGFR, EGFR, and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
  • Inquiry Price
Size
QTY
PP 3
T231765334-30-5
PP 3 is a Negative control for the Src kinase inhibitor PP 2
  • Inquiry Price
Size
QTY
CUDC-101
CUDC101, CUDC 101
T31081012054-59-9
CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4 nM, 2.4 nM, and 15.7 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
FIIN-3
T34661637735-84-2
FIIN-3, an irreversible inhibitor of FGFR (Fibroblast Growth Factor Receptor), is a chemical compound designed to bind permanently to FGFR, thereby inhibiting its activity and potential downstream signaling pathways.
  • Inquiry Price
Size
QTY
avitinib maleate
T37211557268-88-8
Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor.
  • Inquiry Price
Size
QTY